Clinical Trial Update: Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating standard of care with or without CTS-1027 in hepatitis C patients who did not respond to prior therapy; the study was terminated and re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• CTS-1027

Snippet

Sponsor: Conatus Pharmaceuticals Inc. | Conditions: Hepatitis C | Phase 2 | Status: TERMINATED | Results posted: 2012-05-30